Analyzing Thursday Top Gaining Stocks

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  20 Feb 2025
 

FibroGen $FGEN emerged as the day standout performer, surging an impressive 37.44% to close at $0.77 per share on massive volume of 119.36 million shares - dramatically above its average daily volume of 1.03 million. This pharmaceutical company's stock soared after announcing the sale of its China subsidiary to AstraZeneca for approximately $160 million. The deal represents a strategic move that strengthens FibroGen's financial position, extending its cash runway into 2027. Investors responded positively to how this transaction allows FibroGen to focus on advancing its oncology pipeline, particularly its first-in-class CD46 targeting antibody drug conjugate (FG-3246) and companion PET imaging agent (FG-3180) for metastatic castration-resistant prostate cancer.

Reborn Coffee $REBN jumped 30.95% to $7.32 on volume of 7.86 million shares, well above its average of 5.07 million. The specialty coffee company announced a significant European expansion strategy being driven through its Dubai operations. The expansion includes new flagship locations in Vienna, Florence, and Prague, with the Prague location scheduled to open in June 2025. This represents Reborn's strategic entry into the Central European market, appealing to investors looking for growth stories in the competitive coffee retail space.

Unity Software $U saw its shares climb 30.41% to $28.00 despite reporting mixed fourth-quarter results. Trading volume hit 58.25 million shares compared to an average of 8.26 million. The game development platform reported a quarterly loss of 30 cents per share, which actually beat analyst expectations. While revenue was down year-over-year, the company topped revenue estimates by 5.87%, showing resilience in its business model. Notably, the stock's dramatic rise came despite some weakness in game development revenue and lower-than-expected Q1 guidance, suggesting investors may be focusing on long-term potential rather than short-term challenges.

Aptose Biosciences $APTO gained 26.75% to close at $0.19 on extremely heavy volume of 178.89 million shares versus its average of 5.52 million. The penny stock rallied after announcing positive developments in its Phase 1/2 TUSCANY trial. Specifically, the Cohort Safety Review Committee approved escalating from 40mg to 80mg dosing of tuspetinib in combination with venetoclax and azacitidine (the TUSVENAZA triplet therapy) for acute myeloid leukemia (AML) patients. This progress in developing a potential frontline therapy for a diverse population of newly diagnosed AML patients fueled investor optimism.

Travel technology company Sabre $SABR advanced 22.42% to $4.15 on volume of 10.52 million shares compared to its average of 3.20 million. The company released its fourth-quarter earnings results, which showed mixed performance but impressed investors with its forward guidance. Sabre projected $700 million in adjusted EBITDA for 2025, focusing on achieving double-digit growth in both air and hotel bookings. The company's strategic initiatives to streamline operations and capitalize on the continued recovery in global travel appear to be gaining traction with investors.